During the past decade, Retina Research Institute of Texas conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 22 clinical trials were completed, i.e. on average, 40.7% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 19 clinical trials were completed. i.e. 70.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Research Institute of Texas" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Kodiak Sciences Inc" with 6 trials sponsored, "Allergan" with 3 trials sponsored, "Apellis Pharmaceuticals, Inc." with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Research Institute of Texas" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Duke University" with 1 trials as a collaborator, "Lexitas Pharma Services, Inc." with 1 trials as a collaborator and "MEDARVA Foundation" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Retina Research Institute of Texas" are "Geographic Atrophy" (13 trials), "Diabetic Macular Edema" (11 trials), "Macular Degeneration" (9 trials), "Diabetic Retinopathy" (6 trials) and "Macular Edema" (5 trials). Many other conditions were trialed in "Retina Research Institute of Texas" in a lesser frequency.

Most popular intervention types in "Retina Research Institute of Texas" are "Drug" (57 trials), "Other" (16 trials), "Procedure" (5 trials), "Biological" (3 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (15 trials), "Aflibercept" (11 trials), "Faricimab" (8 trials), "KSI-301" (6 trials) and "Placebo" (6 trials). Other intervention names were less common.

The vast majority of trials in "Retina Research Institute of Texas" are 63 trials for "All" genders.

Currently, there are NaN active trials in "Retina Research Institute of Texas". undefined are not yet recruiting, 3 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Retina Research Institute of Texas, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Research Institute of Texas, 11 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".